Recursion announced that Namandje Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion’s Board of Directors, effective as of March 15th. Namandje Bumpus served as the FDA’s Principal Deputy Commissioner until December 31, 2024, after joining the agency in August 2022 as Chief Scientist. Elaine Sun is currently the COO and CFO at Mammoth Biosciences.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Recursion Pharmaceuticals call volume above normal and directionally bullish
- Cathie Wood’s ARK Investment buys 35K shares of Recursion Pharmaceuticals today
- Cathie Wood Capitalizes on Pullback in Tempus AI to Buy Additional Stock Worth $14.4M
- Recursion Pharmaceuticals’ Earnings Call Highlights Growth
- Recursion Pharmaceuticals Reports Mixed 2024 Financial Results